Trials / Completed
CompletedNCT07023107
NLR and PLR Levels Following PENG Block in Hip Arthroplasty
Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Poznan University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 60 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Effect of PENG block on NLR and PLR following hip arthroplasty
Detailed description
The NLR is a sensitive indicator of inflammation confirmed in numerous studies and has a predictive and prognostic value. NLR is a cheap, simple, fast-acting, readily available stress and inflammation parameter with high sensitivity and low specificity. Dynamic changes in the NLR precede the clinical state by several hours and may alert clinicians to the ongoing pathological process early. NLR is a new promising marker of cellular immune activation, an important indicator of stress and systemic inflammation. It opens a new dimension for clinical medicine, enabling a better understanding of the biology of inflammation, the linkage and antagonism between innate and adaptive immunity, and their clinical consequences for health and disease. NLR is affected not only by surgical trauma but also by the method of anesthesia. In recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasized. However, there have been very few studies evaluating the effect of various methods of anesthesia on the NLR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.9% Sodium Chloride Injection | After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride |
| DRUG | Ropivacaine 0.2% Injectable Solution | After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine |
Timeline
- Start date
- 2025-06-16
- Primary completion
- 2025-12-09
- Completion
- 2025-12-09
- First posted
- 2025-06-15
- Last updated
- 2025-12-29
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT07023107. Inclusion in this directory is not an endorsement.